ZA201500995B - Low dose pharmaceutical composition - Google Patents
Low dose pharmaceutical compositionInfo
- Publication number
- ZA201500995B ZA201500995B ZA2015/00995A ZA201500995A ZA201500995B ZA 201500995 B ZA201500995 B ZA 201500995B ZA 2015/00995 A ZA2015/00995 A ZA 2015/00995A ZA 201500995 A ZA201500995 A ZA 201500995A ZA 201500995 B ZA201500995 B ZA 201500995B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- low dose
- dose pharmaceutical
- low
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN495MU2014 IN2014MU00495A (enrdf_load_html_response) | 2014-02-12 | 2015-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201500995B true ZA201500995B (en) | 2015-12-23 |
Family
ID=52544516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2015/00995A ZA201500995B (en) | 2014-02-12 | 2015-02-12 | Low dose pharmaceutical composition |
Country Status (3)
Country | Link |
---|---|
IN (1) | IN2014MU00495A (enrdf_load_html_response) |
WO (1) | WO2015121649A1 (enrdf_load_html_response) |
ZA (1) | ZA201500995B (enrdf_load_html_response) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
CA3068936A1 (en) * | 2017-07-05 | 2019-01-10 | Novartis Ag | Novel pharmaceutical composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX349923B (es) * | 2009-04-03 | 2017-08-21 | Hoffmann La Roche | Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas. |
US20130172375A1 (en) * | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
-
2015
- 2015-02-12 WO PCT/GB2015/050384 patent/WO2015121649A1/en active Application Filing
- 2015-02-12 ZA ZA2015/00995A patent/ZA201500995B/en unknown
- 2015-02-12 IN IN495MU2014 patent/IN2014MU00495A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015121649A1 (en) | 2015-08-20 |
IN2014MU00495A (enrdf_load_html_response) | 2015-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201605300B (en) | Pharmaceutical compositions comprising azd9291 | |
GB201618482D0 (en) | Pharmaceutical compositions | |
GB201419257D0 (en) | Pharmaceutical compositions | |
GB201409471D0 (en) | Pharmaceutical composition | |
IL249553A0 (en) | Pharmaceutical preparations | |
SG11201605366QA (en) | Pharmaceutical composition containing pyridylaminoacetic acidcompound | |
GB201409488D0 (en) | Pharmaceutical composition | |
GB201409485D0 (en) | Pharmaceutical composition | |
HUE046729T2 (hu) | Mirabegront tartalmazó gyógyszerkészítmény | |
GB201521462D0 (en) | Pharmaceutical composition | |
GB201506526D0 (en) | Medicinal composition | |
ZA201502073B (en) | Pharmaceutical composition | |
IL250817A0 (en) | pharmaceutical preparations | |
ZA201508726B (en) | Pharmaceutical composition | |
GB201515310D0 (en) | Pharmaceutical composition | |
GB201520862D0 (en) | Pharmaceutical composition | |
PT3200772T (pt) | Composições farmacêuticas compreendendo alpelisib | |
PT3089740T (pt) | Composição farmacêutica | |
ZA201500995B (en) | Low dose pharmaceutical composition | |
SG10201504332VA (en) | Pharmaceutical Composition | |
SG11201608123VA (en) | Pharmaceutical composition for external use | |
SG11201608124XA (en) | Pharmaceutical composition for external use | |
GB201521456D0 (en) | Pharmaceutical composition | |
SG11201608122PA (en) | Pharmaceutical composition for external use | |
SG2014014872A (en) | Pharmaceutical compositions |